Literature DB >> 29968231

Production and characterization of drug-loaded toroidal vortices from a novel ocular drug delivery device.

Matthew J Herpin1, Dominik Ebi2, Noel T Clemens2, Hugh D C Smyth3.   

Abstract

For the last several decades, the predominant method for delivering medicine to the surface of the eye has been the standard multiuse eye dropper. While being the most popular, this method has significant limitations. Recently, an effort has been made to explore the use of a directed toroidal vortex or "smoke ring" aerosol delivery system that may help overcome these limitations and enable delivery of precise amounts of formulation and drug to the ocular surface. Promising preliminary in vitro studies indicated dosing control, but the physical characteristics of the toriodal aerosol device performance and impaction forces related to patient comfort have yet to be established. Here, we experimentally investigate the mechanics and dynamics of these ocular aerosol vortices, including translational and rotational velocities, spatial droplet size distributions, and relative impaction forces in order to optimize the device performance and evaluate potential for clinical use. Maximal droplet velocity at various actuation forces was determined, and they were found to be all less than 6 m/s even at the highest actuation forces. Moreover, plume impaction forces were determined across a range of conditions and were all less than about 4.5 μN. Collectively, these studies showed that the physical and mechanical properties of the emitted drug-loaded vortices would be suitable for ocular administration.

Entities:  

Keywords:  Drug-device combination products; Ocular drug delivery device; Ophthalmic aerosol delivery; Precision dosing; Toroidal vortex

Mesh:

Substances:

Year:  2018        PMID: 29968231     DOI: 10.1007/s13346-018-0553-1

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  21 in total

1.  Comparative in vitro investigation of the forces exerted by eye drops and eye spray.

Authors:  F Müller; M Wagner; R H H Neubert
Journal:  Pharmazie       Date:  2005-08       Impact factor: 1.267

2.  Characterization of the force effect of aqueous and oily eye drops.

Authors:  F Müller; M Wagner; R H H Neubert
Journal:  Pharmazie       Date:  2005-04       Impact factor: 1.267

Review 3.  Challenges and obstacles of ocular pharmacokinetics and drug delivery.

Authors:  Arto Urtti
Journal:  Adv Drug Deliv Rev       Date:  2006-09-26       Impact factor: 15.470

4.  Mist delivery of eye medication to the anterior segment.

Authors:  James F Collins; Darlene A Dartt; Reza Dana
Journal:  Am J Ophthalmol       Date:  2007-07       Impact factor: 5.258

5.  Performance of the vibrating membrane aerosol generation device: Aeroneb Micropump Nebulizer.

Authors:  Guifang Zhang; Anand David; Timothy Scott Wiedmann
Journal:  J Aerosol Med       Date:  2007

6.  Evaluation of impaction force of nasal sprays and metered-dose inhalers using the Texture Analyser.

Authors:  Changning Guo; Wei Ye; John Kauffman; William H Doub
Journal:  J Pharm Sci       Date:  2009-08       Impact factor: 3.534

7.  The influence of drop size of cyclopentolate, phenylephrine and tropicamide on pupil dilatation and systemic side effects in infants.

Authors:  O Elibol; T Alçelik; N Yüksel; Y Caglar
Journal:  Acta Ophthalmol Scand       Date:  1997-04

8.  Precision Ocular Drug Delivery Via Aerosol Ring Vortices.

Authors:  Matthew J Herpin; Hugh D C Smyth
Journal:  Pharm Res       Date:  2017-08-07       Impact factor: 4.200

Review 9.  Anterior eye segment drug delivery systems: current treatments and future challenges.

Authors:  Sarah A Molokhia; Samuel C Thomas; Kevin J Garff; Kenneth J Mandell; Barbara M Wirostko
Journal:  J Ocul Pharmacol Ther       Date:  2013-03       Impact factor: 2.671

10.  Bioavailability of vitamin B using a small-volume nebulizer ophthalmic drug delivery system.

Authors:  Monte Kahn
Journal:  Clin Exp Ophthalmol       Date:  2005-08       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.